XNASQDEL
Market cap3.10bUSD
Jan 08, Last price
46.03USD
1D
-1.88%
1Q
9.67%
Jan 2017
114.89%
Name
QuidelOrtho Corp
Chart & Performance
Profile
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2023‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 2,997,800 | 3,266,000 | |||||||
Cost of revenue | 2,513,400 | 2,141,500 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 484,400 | 1,124,500 | |||||||
NOPBT Margin | 16.16% | 34.43% | |||||||
Operating Taxes | (19,000) | 187,200 | |||||||
Tax Rate | 16.65% | ||||||||
NOPAT | 503,400 | 937,300 | |||||||
Net income | (10,100) | 548,700 | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 4,400 | (47,900) | |||||||
BB yield | -0.09% | 0.97% | |||||||
Debt | |||||||||
Debt current | 166,500 | 207,500 | |||||||
Long-term debt | 2,646,700 | 2,803,600 | |||||||
Deferred revenue | 400 | 9,400 | |||||||
Other long-term liabilities | 84,000 | 74,400 | |||||||
Net debt | 2,638,500 | 2,645,100 | |||||||
Cash flow | |||||||||
Cash from operating activities | 280,200 | 885,300 | |||||||
CAPEX | (209,300) | (140,900) | |||||||
Cash from investing activities | (187,600) | (1,644,200) | |||||||
Cash from financing activities | (265,800) | 252,000 | |||||||
FCF | |||||||||
Balance | |||||||||
Cash | 167,300 | 345,000 | |||||||
Long term investments | 7,400 | 21,000 | |||||||
Excess cash | 24,810 | 202,700 | |||||||
Stockholders' equity | 2,157,900 | 2,130,300 | |||||||
Invested Capital | 7,678,790 | 7,588,800 | |||||||
ROIC | 6.56% | 12.35% | |||||||
ROCE | 6.13% | 14.05% | |||||||
EV | |||||||||
Common stock shares outstanding | 66,800 | 57,400 | |||||||
Price | 73.70 | 85.67 | |||||||
Market cap | 4,923,160 | 4,917,458 | |||||||
EV | 7,561,660 | 7,562,558 | |||||||
EBITDA | 941,600 | 1,408,100 | |||||||
EV/EBITDA | 8.03 | 5.37 | |||||||
Interest | 178,900 | 75,700 | |||||||
Interest/NOPBT | 36.93% | 6.73% |